Rosenbaum et al., 2017 - Google Patents

The evolving role of companion diagnostics for breast cancer in an era of next-generation omics

Rosenbaum et al., 2017

View HTML
Document ID
10590681367122520937
Author
Rosenbaum J
Weisman P
Publication year
Publication venue
The American journal of pathology

External Links

Snippet

A companion diagnostic is a test for a specific biomarker—approved by the United States Food and Drug Administration—qualifying a patient to receive a specific, associated therapy. As interest has grown in precision medicine over the past decade, the principle of …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Similar Documents

Publication Publication Date Title
Di Nicolantonio et al. Precision oncology in metastatic colorectal cancer—from biology to medicine
Camidge et al. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
Collins et al. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics
Taube et al. Implications of the tumor immune microenvironment for staging and therapeutics
Russo et al. The molecular profiling of solid tumors by liquid biopsy: A position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies
Yu et al. PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer
Keysar et al. Regulation of head and neck squamous cancer stem cells by PI3K and SOX2
Mamessier et al. Early lesions of follicular lymphoma: a genetic perspective
Parra et al. Immunohistochemical and image analysis-based study shows that several immune checkpoints are co-expressed in non–small cell lung carcinoma tumors
Deschoolmeester et al. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy
Lee et al. Proteomics and biomarkers in clinical trials for drug development
Rosenbaum et al. The evolving role of companion diagnostics for breast cancer in an era of next-generation omics
Capdevila et al. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era
Reyes et al. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers
Yang et al. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
Trédan et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study
Kulesza et al. Emerging concepts in the pathology and molecular biology of advanced non–small cell lung cancer
George et al. The discovery of biomarkers in cancer immunotherapy
Mistry et al. Beyond the message: advantages of snapshot proteomics with single‐cell mass cytometry in solid tumors
Tessari et al. Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients
AU2018284125A1 (en) Method for determining the susceptibility of a patient suffering from proliferative disease to treatment using an agent which targets a component of the PD-1/PD-L1 pathway
Roviello The distinctive nature of adenocarcinoma of the lung
Höller et al. Diagnostic and prognostic biomarkers of luminal breast cancer: Where are we now?
Christodoulou et al. Evaluation of the insulin-like growth factor receptor pathway in patients with advanced breast cancer treated with trastuzumab
Lee et al. Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers